AzTrials
AzTrials

Postoperative Neurocognitive DysfunctionNCT06704451

Perioperative IL-33 is Associated with the Early Stage of Postoperative Neurocognitive Dysfunction After Major Abdominal Surgery

An observational study of Postoperative Neurocognitive Dysfunction and Cognitive Dysfunction, run by First Affiliated Hospital of Kunming Medical University at 1 site in China.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Perioperative neurocognitive dysfunction(PND) are common complications of major surgery among patients, could be a long-term disease, which sometimes lasts for several years, and it is meaningful to find a biomarker of PND at the early stage.As far as we know, the relationship between IL-33 and PND is not clear yet in… Read more about this study

Who is it for?
Any age
How many people
150 participants
Where
1 siteChina
Study dates
18 Aug 2014to 30 Dec 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Abdominal surgery patients

Who may be able to join

None listed.

Who cannot join

  • history of mental diseases;
  • patients with current Neurological disease;
  • patients who refused or were unable to finish the neurocognitive evaluation;
  • preoperative Mini-Mental Stare Examination (MMSE) less than required score (illiteracy <17; primary school < 20; middle school and higher < 24).

Trial locations and contacts

1 site in 1 country.

China1 site, 1 recruiting
  • The first affiliated hospital of KUNMING medical university

    Kunming, Yunnan, 650032

    Haixia Jiang, +86-18875200060, 18875200060@163.com

    Recruiting

Other trials in China

About this study

Perioperative neurocognitive dysfunction(PND) are common complications of major surgery among patients, could be a long-term disease, which sometimes lasts for several years, and it is meaningful to find a biomarker of PND at the early stage.As far as we know, the relationship between IL-33 and PND is not clear yet in the gastrointestinal and hepatic area. Thus, the investigators designed this study to find out the association between IL-33 and occurrence of PND, and determine whether IL-33 could be a biomarker of the early stage of PND.Study population included 150 subjects. Neuropsychological questionnaire were administrated one day before surgery and three days after surgery. And the end of the operation peripheral venous blood was sampled to measure IL-33 inflammatory protein expression in peripheral blood monocytes. Analyze the data and draw conclusions.

Read the detailed description

A total of 150 patients scheduled for Abdominal surgery gave written informed consent and were enrolled in this study.

Common demographic factors were collected when the patients were admitted to the hospital, for example, age, gender, body mass index (BMI), and education level. Moreover, the hemocyte indexes, hepatic and renal functions were assessed by blood routine examination 1 day before and 3 days after the surgery.

To evaluate the patients'neurocognitive levels, a well-trained investigator performed a questionnaire to roundly assess their neurocognitive functions 1 day before and 3 days after the surgery. The questionnaire included: (1) Mini-Mental State Examination (MMSE); (2) Hopkins Verbal Learning Test-Revised, testing ability of Verbal learning and memory skills; (3) Brief Visuospatial Memory Test-Revised, testing ability of Visuospatial memory; (4) Trail Making Test; (5) Digital Scope Test; (6) Word Delayed Recall Test, testing ability of long-memory; (7) Word Delayed Interference Test;(8) Image Delayed Recall Test, testing ability of delay recall; (9) Verbal Fluency Test, testing fluency and executive function. At the very beginning, patients with severe cognitive dysfunction were excluded by the lower MMSE score than we required. Each qualified patient gets scores of these tests preoperatively and postoperatively. The investigators collected all of these scores and then obtained the standard deviation (SD) of every preoperative test. The investigators defined a worse test performance as a negative changed score, with an absolute value larger than 1.5 times SD. Patients with no less than two nega- tive changed scores, except for MMSE, were diagnosed as PND . According to this standard, the investigators divided the participants into the PND group and the non-PND group. Finally, the investigators defined two decreased scores as mild PND and more than two decreased scores as severe PND.

Patients got the same preoperative preparation, including ECG monitoring, blood oxygen saturation monitoring, arterial blood pressure, and central venous pressure monitoring. As for the anesthesia method, the investigators took combined anesthesia of inhalation and intravenous. The main anesthetic included sevoflurane, propofol, cisatracurium besylate or rocuronium bromide , and lidocaine for topical anesthesia. During the surgery, the patients were given mechanical ventilation at 12 times/min, with a tidal volume of 6-8ml/kg. Systemic arterial blood pressure was measured via radial artery catheterization. After induction of anesthesia, a central venous catheter was inserted for monitoring central venous pressure (CVP) and fluid management.

At the end of the operation peripheral venous blood was sampled to measure IL-33 expression in peripheral blood monocytes.After the surgery, the surgery time and the anesthesia time were recorded.

PND was diagnosed using the same definition as used in the ISPOCD1-study and previous other studies. To quantify practice effect, baseline scores were compared with subsequent test results three days later in control subjects. For patients, preoperative scores were compared with postoperative test results, subtracted the average practice effect from these changes, and then divided the result by the control-subject SD to obtain a Z score for each test. The test results were adjusted so that a positive Z score indicated deterioration from the baseline test. The Z scores of all tests in an individual patient were then summarized and divided by the SD for this sum of Z scores in the control subjects, creating a combined Z score. A patient was defined as having POCD when two Z scores in individual tests or the combined Z score were 2 or more.

Statistical analysis A continuous outcome was expressed as the mean ± SE, while a categorical outcome was expressed as percentages or frequencies. Differences in continuous and categorical outcomes were tested using the one-way analysis of variance and Chi square analysis, respectively. The unpaired Student t test, paired T test, analysis of variance and Pearson correlation analysis were performed on normally distributed data. Case-control differences in nominal data were evaluated with the Chi square test. Multivariate Cox regression analysis was done for predictors of adverse events. The IL-33 and neurobehavioral scores were compared using ROC curves. Kaplan-Meier curves were used for correlation with POCD. All statistical analyses were performed with SPSS 21.0 (IBM Inc.) and P < 0.05 was considered signifcant.

Keywords
Interleukin-33, Postoperative Neurocognitive Dysfunction, Postoperative Complications, Inflammasomes
Medical subject headings
Cognitive Dysfunction, Postoperative Complications

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The association between peripheral blood IL-33 inflammasome level and postoperative cognitive dysfunction

    Postoperative cognitive dysfunction (POCD) was defined by Z scores. The method of Z scores is as follows:

    A patient was defined as having POCD when two Z scores in individual tests or the combined Z score were 2 or more.

    Neuropsychological tests included MMSE,Hopkins Verbal Learning Test-Revised, Brief Visuospatial Memory Test-Revised,Trail Making Test, Digital Scope Test,Word Delayed Recall Test, Word Delayed Interference Test, Image Delayed Recall Test. Preoperative scores were compared with postoperative test results, subtracted the average practice effect from these changes, and then divided the result by the control-subject standard deviation to obtain a Z score for each test. The Z scores of all tests in an individual patient were then summarized and divided by the standard deviation for this sum of Z scores in the control subjects, creating a combined Z score.

    The test results were adjusted so that a positive Z score indicated deterioration from the baseline test.

    Measured: Expected completion date: June 18, 2025

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Nov 2024
  2. Study start18 Aug 2014
  3. Primary completion18 Jun 2025 (estimated)
  4. Study completion30 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06704451
Sponsor's protocol ID
1stKunmingMC1
Status last verified
Oct 2024
First submitted
27 Oct 2024
Last updated
26 Nov 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Postoperative Neurocognitive Dysfunction and Cognitive Dysfunction, run by First Affiliated Hospital of Kunming Medical University at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The association between peripheral blood IL-33 inflammasome level and postoperative cognitive dysfunction (time frame: Expected completion date: June 18, 2025). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Nov 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in